Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey.
Adult
Africa
Allied Health Personnel
Asia
Betacoronavirus
COVID-19
Coronavirus Infections
/ transmission
Europe
Eye Protective Devices
Female
Gloves, Protective
Headache
/ etiology
Health Personnel
Hot Temperature
Humans
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Intensive Care Units
Male
Masks
/ adverse effects
Middle Aged
North America
Nurses
Occupational Health
Oceania
Pandemics
Personal Protective Equipment
/ adverse effects
Personnel Staffing and Scheduling
Physicians
Pneumonia, Viral
/ transmission
Respiratory Protective Devices
/ adverse effects
SARS-CoV-2
South America
Surgical Attire
Surveys and Questionnaires
Thirst
COVID-19
Health care workers
Intensive care
Personal protective equipment
Safety
Journal
Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
04
2020
revised:
08
06
2020
accepted:
10
06
2020
pubmed:
23
6
2020
medline:
2
10
2020
entrez:
23
6
2020
Statut:
ppublish
Résumé
To survey healthcare workers (HCW) on availability and use of personal protective equipment (PPE) caring for COVID-19 patients in the intensive care unit (ICU). A web-based survey distributed worldwide in April 2020. We received 2711 responses from 1797 (67%) physicians, 744 (27%) nurses, and 170 (6%) Allied HCW. For routine care, most (1557, 58%) reportedly used FFP2/N95 masks, waterproof long sleeve gowns (1623; 67%), and face shields/visors (1574; 62%). Powered Air-Purifying Respirators were used routinely and for intubation only by 184 (7%) and 254 (13%) respondents, respectively. Surgical masks were used for routine care by 289 (15%) and 47 (2%) for intubations. At least one piece of standard PPE was unavailable for 1402 (52%), and 817 (30%) reported reusing single-use PPE. PPE was worn for a median of 4 h (IQR 2, 5). Adverse effects of PPE were associated with longer shift durations and included heat (1266, 51%), thirst (1174, 47%), pressure areas (1088, 44%), headaches (696, 28%), Inability to use the bathroom (661, 27%) and extreme exhaustion (492, 20%). HCWs reported widespread shortages, frequent reuse of, and adverse effects related to PPE. Urgent action by healthcare administrators, policymakers, governments and industry is warranted.
Identifiants
pubmed: 32570052
pii: S0883-9441(20)30592-X
doi: 10.1016/j.jcrc.2020.06.005
pmc: PMC7293450
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-75Subventions
Organisme : Wellcome Trust
ID : 205214/Z/16/Z
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Tabah has nothing to disclose, Dr. Ramanan has nothing to disclose, Prof. Laupland has nothing to disclose, Dr. Buetti has nothing to disclose, Dr. Cortegiani has nothing to disclose, Mr. Mellinghoff has nothing to disclose, Dr. Conway Morris reports grants from Wellcome Trust, during the conduct of the study; Dr. Camporota has nothing to disclose, Dr. Zappella has nothing to disclose, Dr. Vidal has nothing to disclose, Dr. Elhadi has nothing to disclose, Dr. Povoa reports personal fess from Orion, personal fees from Pfizer and personal fees from Technofage, Dr. Amrein reports grants, personal fees and other from Fresenius Kabi, personal fees from Vifor Pharma, personal fees from Shire now part of Takeda, outside the submitted work, Dr. Derde reports grants from European Union, grants from ZonMw, outside the submitted work, Guy Francoishas nothing to disclose, Dr. Bassetti reports grants and personal fees from Pfizer, grants and personal fees from MSD, grants and personal fees from Menarini, grants and personal fees from Angelini, personal fees from Astellas, personal fees from Nabriva, grants and personal fees from Paratek, personal fees from Gilead, personal fees from Basilea, personal fees from Cidara, personal fees from Molteni, outside the submitted work; Dr. Ssi Yan Kai has nothing to disclose, Dr. De Waelereports grants from Research Foundation Flanders, during the conduct of the study; other from Bayer, other from Pfizer, other from MSD, other from Grifols, other from Accelerate, outside the submitted work;.
Références
Emerg Infect Dis. 2020 Jul;26(7):1583-1591
pubmed: 32275497
BMJ. 2020 Apr 3;369:m1367
pubmed: 32245847
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Can J Anaesth. 2020 May;67(5):568-576
pubmed: 32052373
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Cochrane Database Syst Rev. 2020 Apr 15;4:CD011621
pubmed: 32293717
JAMA. 2020 May 19;323(19):1915-1923
pubmed: 32275295
N Engl J Med. 2020 Apr 30;382(18):e41
pubmed: 32212516
Anaesthesia. 2020 Aug;75(8):1121-1122
pubmed: 32496625
PLoS One. 2019 Jan 22;14(1):e0210775
pubmed: 30668567
JAMA. 2020 Jun 2;323(21):2133-2134
pubmed: 32259193